Interní Med. 2015; 17(4): 200-203

New oral anticoagulants - hematologist’s perspective

MUDr.Antonín Hluší, Ph.D., Mgr.Luděk Slavík, Ph.D., MUDr.Miroslava Palová, doc.MUDr.Věra Krčová, CSc.
Hemato-onkologická klinika FN a LF UP Olomouc

The standard anticoagulation therapy with warfarin or heparin is often replaced by new directly acting drugs known as the new oral anticoagulants

(NOAC) in recent years. For routine clinical use direct thrombin inhibitor dabigatran and direct inhibitors of activated factor

Xa rivaroxaban and apixaban are currently used. NOAC are administered mostly by the internists, particularly cardiologists, neurologists,

orthopedists and angiologists. Hematologist is often involved in the issue, if interpretation of hemostatic parameters in anticoagulant

therapy monitoring or therapy related hemorrhagic complications is necessary.

Keywords: anticoagulation therapy, bleeding, NOAC, monitoring

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hluší A, Slavík L, Palová M, Krčová V. New oral anticoagulants - hematologist’s perspective. Interní Med. 2015;17(4):200-203.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://www.sukl.cz/medication.
    2. van Ryn J Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116-1127. Go to original source... Go to PubMed...
    3. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013, 11: 756-760. Go to original source... Go to PubMed...
    4. Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127-136. Go to original source... Go to PubMed...
    5. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159: 427-429. Go to original source... Go to PubMed...
    6. Garcia D, Barrett YC, Ramacciotti E, et al. Laboratory Assessment of the Anticoagulant Effects of the Next Generation of Oral Anticoagulants. J Thromb Haemost 2013; 11(2): 245-252. Go to original source... Go to PubMed...
    7. Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot trombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110(2): 308-315. Go to original source... Go to PubMed...
    8. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997. Go to original source... Go to PubMed...
    9. Kawabata M, Yokoyama Y, Sasano T, et al. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. J Cardio 2013; 62(2): 121-126. Go to original source... Go to PubMed...
    10. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-198. Go to original source... Go to PubMed...
    11. Samama MM, Contant G, Spiro TE, et al. Laboratory Assessment of Rivaroxaban: a Review. Thromb J 2013; 11(1): 11. Go to original source... Go to PubMed...
    12. Pisters R, Lane DA, Nieuwelaat R, et al. A novel, user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; 138: 1093-1100. Go to original source... Go to PubMed...
    13. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European heart journal 2013; 34(27): 2094-2106. Go to original source... Go to PubMed...
    14. Steiner T, Böhm M, Dichgans M, et al. Recommendations for the Emergency Management of Complications Associated with the New Direct Oral Anticoagulants (DOACs), Apixaban, Dabigatran and Rivaroxaban. Clin Res Cardiol Off J Ger Card Soc 2013; 102(6): 399-412. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.